Evidence map›Paper›PMID 33002560›Full record

ArticleThe Journal of infection2020

The role of Frailty on Adverse Outcomes Among Older Patients with COVID-19.

Harun Kundi, Elif Hande Özcan Çetin, Uğur Canpolat, Sevgi Aras, Osman Celik, Naim Ata, Suayip Birinci, Serkan Çay, Özcan Özeke, Ibrahim Halil Tanboğa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Harun KundiAnkara City Hospital, Department of Cardiology, Ankara, Turkey. Electronic address: harunkundi@hotmail.com.
Elif Hande Özcan ÇetinAnkara City Hospital, Department of Cardiology, Ankara, Turkey.
Uğur CanpolatHacettepe University, Department of Cardiology, Ankara, Turkey.
Sevgi ArasAnkara University, Department of Geriatric Medicine, Ankara, Turkey.
Osman CelikRepublic of Turkey Ministry of Health, Ankara, Turkey.
Naim AtaRepublic of Turkey Ministry of Health, Ankara, Turkey.
Suayip BirinciRepublic of Turkey Ministry of Health, Ankara, Turkey.
Serkan ÇayUniversity of Health Sciences, Ankara City Hospital, Department of Cardiology, Ankara, Turkey.
Özcan ÖzekeUniversity of Health Sciences, Ankara City Hospital, Department of Cardiology, Ankara, Turkey.
Ibrahim Halil TanboğaNişantaşı University, Hisar Intercontinental Hospital, Cardiology, Istanbul, Turkey; Ataturk University Biostatistics, Erzurum, Turkey.
Serkan TopaloğluUniversity of Health Sciences, Ankara City Hospital, Department of Cardiology, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiagnosis and screening of frailty, a condition characterized by an increased vulnerability to adverse outcomes of COVID-19, has emerged as an essential clinical tool which is strongly recommended by healthcare providers concerned with hospitalized elderly population. The data showing the role of frailty in patients infected with COVID-19 is needed.

methodsThis was a nationwide cohort study conducted at all hospitals in Turkey. All COVID-19 hospitalized patients (≥ 65 years) were included. Patients who were alive and not discharged up to July 20, 2020, were excluded. The frailty was assessed by using the "Hospital Frailty Risk Score" (HFRS). Patients were classified into three risk groups of frailty based on previously validated cut points as low (<5 points), intermediate (5-15 points), and high (>15 points). Additionally, patients who had the HFRS of ≥5 were defined as frail. The primary outcome was in-hospital mortality rates by frailty group.

resultsBetween March 11, 2020, and June 22, 2020, a total of 18,234 COVID-19 patients from all of 81 provinces of Turkey were included. Totally, 12,295 (67.4%) patients were defined as frail (HFRS of >5) of which 2,801 (15.4%) patients were categorized in the highest level of frailty (HFRS of >15). Observed in-hospital mortality rates were 697 (12.0%), 1,751 (18.2%) and 867 (31.0%) in low, intermediate and high hospital frailty risk, respectively (p<0.001). Compared with low HFRS (<5), the adjusted odds ratios for in-hospital mortality were 1.482 (1.334-1.646) for intermediate HFRS (5-15) and 2.084; 95% CI, 1.799-2.413 for high HFRS (>15).

conclusionsAs a claims-based frailty model, the HFRS provides clinicians and health systems, a standardized tool for an effective detection and grading of frailty in patients in COVID-19. A frailty-based tailored management of the older population may provide a more accurate risk categorization for both therapeutic and preventive strategies.

Indexed as

AgedAged, 80 and overCohort StudiesCOVID-19FemaleFrail ElderlyFrailtyGeriatric AssessmentHospitalizationHospital MortalityHumansLength of StayMaleOdds RatioPrevalenceRisk AssessmentCOVID-19Frailty

Identifiers

PMID33002560
PMCPMC7521439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.